IL129387A0 - Methods and compositions for delivery and expression of interferon-alpha nucleic acids - Google Patents

Methods and compositions for delivery and expression of interferon-alpha nucleic acids

Info

Publication number
IL129387A0
IL129387A0 IL12938797A IL12938797A IL129387A0 IL 129387 A0 IL129387 A0 IL 129387A0 IL 12938797 A IL12938797 A IL 12938797A IL 12938797 A IL12938797 A IL 12938797A IL 129387 A0 IL129387 A0 IL 129387A0
Authority
IL
Israel
Prior art keywords
interferon
expression
delivery
compositions
methods
Prior art date
Application number
IL12938797A
Other languages
English (en)
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of IL129387A0 publication Critical patent/IL129387A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
IL12938797A 1996-10-18 1997-10-16 Methods and compositions for delivery and expression of interferon-alpha nucleic acids IL129387A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73381596A 1996-10-18 1996-10-18
PCT/US1997/017928 WO1998017801A1 (en) 1996-10-18 1997-10-16 METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-α NUCLEIC ACIDS

Publications (1)

Publication Number Publication Date
IL129387A0 true IL129387A0 (en) 2000-02-17

Family

ID=24949214

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12938797A IL129387A0 (en) 1996-10-18 1997-10-16 Methods and compositions for delivery and expression of interferon-alpha nucleic acids

Country Status (20)

Country Link
EP (2) EP1591528A3 (hu)
JP (2) JP2001502540A (hu)
KR (1) KR20000049243A (hu)
AR (1) AR013618A1 (hu)
AU (1) AU4808097A (hu)
BR (1) BR9712362A (hu)
CA (1) CA2269100A1 (hu)
CZ (1) CZ131699A3 (hu)
DE (1) DE932679T1 (hu)
ES (1) ES2136583T1 (hu)
HU (1) HUP9904219A2 (hu)
ID (1) ID24500A (hu)
IL (1) IL129387A0 (hu)
NO (1) NO991839L (hu)
NZ (1) NZ335134A (hu)
PL (1) PL332856A1 (hu)
SK (1) SK50699A3 (hu)
TR (1) TR199901190T2 (hu)
WO (1) WO1998017801A1 (hu)
ZA (1) ZA979295B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912925D0 (en) * 1999-06-03 1999-08-04 Angeletti P Ist Richerche Bio Adenoviral vectors encoding interferon and their use in gene therapy
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
SG166117A1 (en) * 2003-12-10 2010-11-29 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
JP2008521907A (ja) 2004-12-03 2008-06-26 シェーリング コーポレイション 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー
CN102886052B (zh) 2006-09-14 2014-07-30 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CA2678409A1 (en) 2007-02-23 2008-08-28 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Inoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
JP2013532152A (ja) 2010-06-15 2013-08-15 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤
JP7264867B2 (ja) 2017-03-31 2023-04-25 アッカニス・バイオテック・エフ・アンド・イー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト 非メラノーマ皮膚癌（ｎｍｓｃ）の予防および治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238778C2 (de) * 1992-11-12 1995-11-02 Max Delbrueck Centrum Vektor zur Expression von therapeutisch relevanten Genen
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
EP1637608B1 (en) * 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
DE4407859C1 (de) * 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
JP2001502540A (ja) 2001-02-27
KR20000049243A (ko) 2000-07-25
BR9712362A (pt) 1999-08-31
EP1591528A3 (en) 2005-11-16
CA2269100A1 (en) 1998-04-30
NO991839D0 (no) 1999-04-16
TR199901190T2 (xx) 1999-07-21
JP2008301832A (ja) 2008-12-18
ES2136583T1 (es) 1999-12-01
HUP9904219A2 (hu) 2000-12-28
ID24500A (id) 2000-07-20
PL332856A1 (en) 1999-10-25
WO1998017801A1 (en) 1998-04-30
EP1591528A2 (en) 2005-11-02
AR013618A1 (es) 2001-01-10
EP0932679A1 (en) 1999-08-04
DE932679T1 (de) 2000-03-09
AU4808097A (en) 1998-05-15
ZA979295B (en) 1998-04-20
NZ335134A (en) 2001-05-25
CZ131699A3 (cs) 1999-07-14
NO991839L (no) 1999-06-15
SK50699A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
EP1015470A4 (en) COMPOSITION AND METHOD FOR DELIVERING NUCLEIC ACIDS
AU4231897A (en) Compositions and methods for delivery of nucleic acids to hepatocytes
EP0948513A4 (en) RECOMBINATION PRODUCT FOR THE DELIVERY OF ANTISENSE NUCLEIC ACIDS AND METHODS OF USE
HUP9801207A3 (en) Therapeutic compositions for transfecting nucleic acids and use thereof
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
IL136454A0 (en) Compositions and methods for inducing gene expression
IL132704A0 (en) Methods and compositions for the selective modification of nucleic acids
AU7980298A (en) Methods and compositions for multiplex amplification of nucleic acids
ZA968907B (en) Compositions and methods for buccal delivery of pharmaceutical agents
HUP0003761A3 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
EP0975371A4 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR MODULATING THE ACTIVATING PROTEIN 1.
AU6544598A (en) Compositions and methods for analysis of nucleic acids
IL135338A0 (en) Methods and compositions for the selective modification of nucleic acids
IL105914A0 (en) Methods and compositions for in vivo gene therapy
AU9692198A (en) Gene delivery compositions and methods
IL114015A0 (en) Inhibitors of interleukin-1beta converting enzyme and pharmaceutical compositions containing the same
HUP9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
GB9422571D0 (en) Haemorrihoidal compositions and method of use
AU2773695A (en) Compositions for and methods of enhancing delivery of nucleic acids to cells
GB9710800D0 (en) Pharmaceutical composition and method of preparing it
IL129387A0 (en) Methods and compositions for delivery and expression of interferon-alpha nucleic acids
EP0781142A4 (en) COMPOSITIONS AND METHOD FOR PROVIDING POLYPEPTIDES
HUP9700810A3 (en) Acids and esters of diosmetin and pharmaceutical compositions containing them